The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

UK-based bispecific immunotherapy developer Immunocore has filed to raise up to $100m in an initial public offering that will enable pharmaceutical firms Eli Lilly and WuXi AppTec to exit. Immunocore is developing T-cell engaging receptors (TCR) antibody treatments for cancer, infectious and autoimmune diseases, and will use some of the IPO takings to advance lead…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.